samedan logo
 
 
spacer
home > pmps > autumn 2007 > tomorrow’s manufacturing
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Tomorrow’s Manufacturing

Andy Chandler, Lanner Group’s Practice Leader for the pharmaceutical sector, looks at how simulation can increase efficiencies and cut costs for pharmaceutical manufacturing both today and in the future

The pharmaceutical companies of today face a completely different set of challenges compared to five years ago. In the past, the onus was firmly placed on increasing outputs to ensure profits, without much thought to achieving manufacturing efficiency. This attitude has had to change as the industry of today faces significant transformation. The spiralling costs of developing new chemical entities (NCEs) has meant that pharmaceutical companies need to cut costs in other areas of the business to ensure that minimal resources are taken away from the research and development divisions of the organisation.

Furthermore, newfound challenges brought about by increased competition, challenging targets, higher customer expectations and shareholder influence have put added pressure on the shoulders of today’s pharmaceutical manufacturers. As a result, when it comes to business, ‘more, cheaper, faster, better’ is often the mantra for today’s pharmaceutical companies. Pharmaceutical companies have also been hit with two major moral pressures. The first comes from the recent report by the Office of Fair Trading which found that the NHS is paying pharmaceutical companies millions of pounds too much for patients’ drugs. The second is a by-product of the internet age, which, due to its mass information immediacy, has seen a sharp increase in consumer awareness and education with regards to illnesses and their treatments.

Therefore, pharmaceutical companies face intense pressure from all angles to both cut the costs of their drugs and speed up production, while being driven by the pressure from regulators and stakeholders alike. This is combined with the need to uphold a credible, professional and responsible company reputation. On the whole, it is fair to say that manufacturers face one of their most difficult periods in recent times.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Andy Chandler is a Senior Consultant with Lanner Group, working globally with pharmaceuticals companies. Andy has been leading and delivering simulation based improvement projects for the last 10 years. These projects focus on minimising cost of new investments and increasing efficiency of existing assets. Andy gained his degree in Mathematics (BSc Hons) from Bristol in 1992, and followed this with an MBA in International Business at Birmingham in 2004.
spacer
Andy Chandler
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

New PFA SonicLine® ultrasonic flowmeters

Flow measurement with ultrasound fast, precise, free from contamination         The new PFA SonicLine® ultrasonic flowmeters assure precise measurement and control of chemical consumption and management of chemical stocks with high reliability. SonicLine® is also ideally suited for accurate batch and dosing processes with high reproducibility.              
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement